Skip to main content

FTC clears J&J acquisition of Cougar Biotechnology


NEW BRUNSWICK, N.J. The Federal Trade Commission has given clearance to the acquisition of a biotechnology company by drug maker Johnson & Johnson.

J&J announced that the FTC had granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to J&J’s acquisition of Los Angeles-based Cougar Biotechnology.

J&J made a tender offer last month to acquire Cougar for $1 billion, or $43 per share, and Cougar’s board recommended that stockholders accept the offer. If J&J manages to acquire a majority of tendered shares, and fulfills other customary conditions, Cougar will become a subsidiary, working with J&J’s biotech division. The tender offer expires at midnight July 2.

This ad will auto-close in 10 seconds